Expression and clinical significance of Ezrin in the serous ovarian cancer

XIE Zhe LI Lan-fang LUO Qing-ya LIU Yi LI Gui-qin WANG Geng-chao MAO Cheng-yi YI Ping*

doi:10.16098/j.issn.0529-1356.2017.01.010

PDF(505 KB)

Acta Anatomica Sinica ›› 2017, Vol. 48 ›› Issue (1) : 54-60. DOI: 10.16098/j.issn.0529-1356.2017.01.010

Cancer Biology

Expression and clinical significance of Ezrin in the serous ovarian cancer

XIE Zhe¹ LI Lan-fang¹LUO Qing-ya² LIU Yi¹ LI Gui-qin¹ WANG Geng-chao³ MAO Cheng-yi²YI Ping^1*

Author information +

History +

Abstract

Objective To investigate the expression feaure of Ezrin in the normal ovarian epithelial tissues and the serous ovarian cancer tissues and evaluate the relationships between Ezrin expression and the clinicopathological characteristics of ovarian cancer patient. Methods The relative Ezrin mRNA- expression was detected by Real-time PCR in 40 specimens of ovarian carcinoma and 27 specimens of normal ovarian epithelial fresh frozen tissues. A total of 134 specimens of paraffin-embeded ovrian cancer tissues and 27 specimens of normal ovarian epithelial tissues were collected,and the Ezrin protein level was examined by immunohistochemistry. The correlation of Ezrin with the clinicopathological characteristics of patients with ovarian cancer was analyzed by SPSS 20.0. Results Both the RNA and protein levels of Ezrin were significantly reduced in ovarian cancer compared to the normal control(P<0.05). Statistical analysis revealed that Ezrin expression had no correlation with age, cytoreduction satisfactory degree and sensitivity of chemotherapy. However there was a significant difference in ezrin protein levels with the disease-free and overall survival (P<0.05). Although ezrin did not serve as an independent predictor for disease progression (HR 1.406, P>0.05) and overall survival (HR 1.260, P>0.05), the expression of Ezrin was negatively correlated with clinical stage,differentiation, and Oentum majus metastasis (P<0.05). Conclusion The down-regulation of Ezrin may play a substantial role in the pathophysiology of serous ovarian cancer. Therefore, it may be used as the potential pre-diagnostic and prognostic marker of ovarian cancer and direct the clinical treatment in the future.

Key words

Ezrin / Serous ovarian cancer / Oentum majus metastasis / Progression free survival / Overal survival / Real-time PCR / Human

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

XIE Zhe LI Lan-fang LUO Qing-ya LIU Yi LI Gui-qin WANG Geng-chao MAO Cheng-yi YI Ping. Expression and clinical significance of Ezrin in the serous ovarian cancer[J]. Acta Anatomica Sinica. 2017, 48(1): 54-60 https://doi.org/10.16098/j.issn.0529-1356.2017.01.010

References

［1］Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths［J］. CA Cancer J Clin, 2011, 61(4): 212-236.

［2］Liang XD, Zeng HX, Zhu HL, et al. Platinum-resistance in advanced epithelial ovarian carcinomas and treatment for different recurrent diseases［J］. Progress in Obstetrics and Gynecology, 2011, 20(11): 841-845. (in Chinese)

梁旭东, 曾浩霞, 祝洪澜, 等. 晚期卵巢上皮癌耐药分析及复发后治疗［J］. 现代妇产科进展, 2011, 20(11): 841-845.

［3］English DP, Menderes G, Black J, et al. Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer［J］. Expert Rev Mol Diagn, 2016, 16(7): 769-782. ［4］Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors［J］. Semin Surg Oncol, 2000, 19(1): 3-10.

［5］Jacobs I, BR Jr. The CA 125 tumour-associated antigen: a review of the literature［J］. Hum Reprod, 1989, 4(1): 1-12.

［6］Ponuwei GA. A glimpse of the ERM proteins［J］. J Biomed Sci, 2016, 23(1): 1-6

［7］Arpin M, Chirivino D, Naba A, et al. Emerging role for ERM proteins in cell adhesion and migration［J］. Cell Adh Migr, 2011, 5(2): 199-206.

［8］Konstantinovsky S, Davidson B, Reich R. Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids［J］. Clin Exp Metastasis, 2012, 29(6): 527-540.

［9］Hunter KW. Ezrin, a key component in tumor metastasis［J］. Trends Mol Med, 2004, 10(5): 201-204.

［10］Meng Y, Lu Z, Yu S, et al. Ezrin promotes invasion and metastasis of pancreatic cancer cells［J］. J Transl Med, 2010, 8(1): 274-276.

［11］Shang X, Wang Y, Zhao Q, et al. siRNA-s target sites selection of ezrin and the influence of RNA- interference on ezrin expression and biological characters of osteosarcoma cells［J］. Mol Cell Biochem, 2012, 364(1): 363-371

［12］Li Q, Gao H, Xu H, et al. Expression of ezrin correlates with malignant phenotype of lung cancer, and in vitro knockdown of ezrin reverses the aggressive biological behavior of lung cancer cells［J］. Tumour Biol, 2012, 33(5): 1493-1504.

［13］Yu Y, Khan J, Khanna C, et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators［J］. Nat Med, 2004, 10(2): 175-181.

［14］Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis［J］. Nat Med, 2004, 10(2): 182-186.

［15］Weng WH, Ahlen J, Astrom K, et al. Prognostic impact of immunohistochemical expression of ezrin in highly malignant soft tissue sarcomas［J］. Clin Cancer Res, 200511(17): 6198-6204.

［16］Kobel M, Langhammer T, Huttelmaier S, et al. Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas［J］. Mod Pathol, 2006, 19(4): 581-587.

［17］Abdou AG, Sakr S, Elwahed MM, et al. Immunohistochemical assessment of ezrin and moesin in colorectal carcinoma［J］. Ultrastruct Pathol, 2016, 40(4): 1-8.

［18］Hiscox S, Jiang WG. Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin［J］. J Cell Sci, 1999, 112(18): 3081-3090.

［19］Chen Z, Fadiel A, Feng Y, et al. Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor［J］. Cancer, 2001, 92(12): 3068-3075.

［20］Moilanen J, Lassus H, Leminen A, et al. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients［J］. Gynecol Oncol, 2003, 90(2): 273-281.

［21］Zhou J, Liu H, Chen Y, et al. Expression and significance of VEGF, miR-205 and target protein Ezrin and Lamin A/C in ovarian cancer［J］. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2014, 39(2): 142-150.